Adrenomedullin (AM) is a multifunctional peptide in human pheochromocytoma. To evaluate whether AM could be an angiogenic factor, we examined its effect on kinases and angiogenic processes. AM induced tyrosine phosphorylation of Akt and mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase1/2 (ERK1/2) by using distinct signaling pathways in human umbilical vein endothelial cells (HUVECs). AM also phosphorylated focal adhesion kinase, and phosphatidylinositol 3′-kinase inhibitor inhibited AM-induced focal adhesion kinase phosphorylation. Pretreatment with high concentrations of AM , a putative AM receptor antagonist, partially suppressed AM-induced phosphorylation of Akt, ERK1/2, and focal adhesion kinase. AM and vascular endothelial growth factor produced increases in DNA synthesis and migration in HUVECs. AM induced tube formation in HUVECs, and its effect was inhibited by pretreatment with phosphatidylinositol 3′-kinase inhibitor or ERK1/2 inhibitor. AM induced sprouting in porcine pulmonary arterial endothelial cells and promoted neovessel formation in a mouse Matrigel plug assay. Inhibitors of phosphatidylinositol 3′-kinase and ERK1/2 inhibited AM-induced endothelial sprouting in vitro and angiogenesis in vivo. AM exerts angiogenic activity through activation of Akt, MAPK, and focal adhesion kinase in endothelial cells.
uman adrenomedullin (AM) is a 52-amino acid peptide that was discovered in pheochromocytoma cells (1) . Although AM was discovered in malignant tissue arising from adrenal medulla, AM mRNA has been shown to be highly expressed in normal tissues such as cardiac atrium and ventricle, aorta, kidney, lung, and uterus as well as in adrenal gland (2, 3) . AM protein is also highly expressed in adrenal gland, atrium, and lung (2) . However, the concentration of immunoreactive AM in aorta and ventricle was <5% of that in adrenal gland, even though a high level of AM mRNA was found in these circulatory system tissues (2) . This fact suggested that AM synthesized in these tissues may be rapidly and H constitutively secreted into the blood or function as an autocrine or paracrine regulator (4) . Indeed, it has been demonstrated that vascular endothelial cells and vascular smooth muscle cells actively synthesize and secrete AM (5, 6) . In addition, the functional AM receptor, composed of calcitonin receptor-like receptor (CRLR) and the receptor activity-modifying protein (RAMP) 2 or RAMP 3 is found in vascular endothelial cells (7, 8) . Thus, AM is actively synthesized and secreted from vascular endothelial and smooth muscle cells and has an autocrine and paracrine role in the vascular system.
It is well established that AM has multiple functions. Intravenous injection of AM causes a potent and long-lasting hypotensive effect in anesthetized rats in vivo (1) . AM also decreases vascular endothelial cell apoptosis and acts as an antiproliferative factor for vascular smooth muscle cells (9, 10) . AM inhibites smooth muscle cell migration (11) . Thus, AM had functions as a regulator in cell differentiation, survival, and growth in the vascular system (12) .
AM is also expressed in the female reproductive tract, especially in the ovarian granulosa cells, uterine epithelial cells, stromal cells, endometrial endothelial cells, uterine smooth muscle cells, and placenta cells (13) . The AM level in uterus was shown to change in accordance with reproductive cycles (14) . The AM mRNA levels increase in the corpus luteum during the midluteal phase and are maintained during early pregnancy (15) . AM also promotes growth of endometrial endothelial cells (16) . Because angiogenesis is actively associated with follicular development, corpus luteum formation, and uterine endometrial proliferation, these findings suggest that the high expression level of AM in uterus and placenta is related to angiogenesis and vasculogenesis in the reproductive tract. Recently, it was reported that AM was induced by tamoxifen and had an angiogenic function in normal uterine endometrium (17) .
In tumor cells, inflammation and hypoxia increase AM expression (18) . The elevated expression of AM is associated with tumor neovascularization in xenografted endometrial tumors and renal cell carcinoma (19, 20) . AM is also a tumor cell survival factor underlying human carcinogenesis (18) . Thus, AM may have a significant role in tumor angiogenesis.
The role of AM in vascular development was demonstrated by an AM gene knockout mouse (21) . In knockout mice, AM is indispensable for vascular morphogenesis during embryonic development (22) . Targeted null mutation of the AM gene is lethal in utero, with extreme hydrops fetalis and cardiovascular abnormalities (21, 22) . Although knockouts of the gene encoding AM result in embryonic lethality in mice due to an absence of blood vessel formation, the biological activity and the signal pathway of AM have not yet been described. Thus, it is known that AM has important roles in tumor angiogenesis, vascular development, and angiogenesis of the female reproductive system. However, the signaling pathway used by AM in vascular angiogenesis has not been reported. In this report, we investigated the angiogenic effect of AM on endothelial cells and the possible mechanisms of AM-induced angiogenesis in vascular endothelial cells. We found that AM-induced angiogenesis in an in vivo experiment and that it induces sprouting through endothelial cell proliferation, migration, and tube formation in cultured endothelial cells. AM-induced angiogenesis occurred through phosphatidylinositol 3′-kinase (PI 3′-kinase)/Akt, extracellular signal-regulated kinase (ERK), and tyrosine phosphorylation of focal adhesion kinase (p125 FAK ). Therefore, we propose that AM induces angiogenesis in endothelial cells through the activation of Akt, ERK, and p125 FAK .
MATERIALS AND METHODS

Materials and cell culture
Fetal bovine serum (FBS) was purchased from Life Technologies (Gaithersburg, MD). Collagenase type II and elastase were purchased from Worthington Biomedical (Freehold, NJ). AM, AM , gelatin, antibiotics, antimycotics, monoclonal mouse anti-human factor VIIIrelated antigen, M199, wortmannin, Matrigel, microcarrier beads, and trypsin-EDTA were from Sigma-Aldrich (St. Louis, MO). Recombinant human vascular endothelial growth factor 165 (VEGF) was purchased from R&D Systems (Minneapolis, MN). Wortmannin and PD98059 were obtained from Calbiochem (San Diego, CA). Antibodies for phospho-specific ERK1/2 (Thr202/Tyr204), Akt, and phospho-specific Akt (Ser473) were purchased from New England Biolabs (Beverly, MA). Antibodies for p125 FAK and phospho-specific p125 FAK (Tyr397) were received from Upstate Biotechnology (Lake Placid, NY). Boyden chambers were purchased from Neuroprobe (Cabin John, MD). Cell culture products and most other biochemical reagents were purchased from Sigma-Aldrich, unless otherwise specified. The primary cultured cells used in this study were between passage 2 and 3. The porcine pulmonary artery endothelial cells (PPAECs) and human umbilical vein endothelial cells (HUVECs) were isolated using methods described previously (23, 24) .
Biochemical analyses
HUVECs were incubated in M199 medium with 1% FBS for 16 h before addition of AM. To measure the activity of mitogen-activated protein kinase (MAPK), and the phosphorylation of Akt and p125 FAK , HUVECs were treated with AM for the indicated times and doses. The treated HUVECs were washed two times with phosphate-buffered saline (PBS), dissolved in sample buffer (50 mM Tris-HCl, [pH 7.5], 100 mM NaCl, 0.1% SDS, 1% NP-40, 50 mM NaF, 1 mM Na 3 VO 4 , 1 µg/ml aprotinin, 1 µg/ml pepstatin, and 1 µg/ml leupeptin), boiled, separated by SDS-PAGE, and transferred to nitrocellulose membrane. The membranes were treated, and the phosphorylation levels were analyzed according to the manufacturer's protocols. All signals were visualized and analyzed by densitometric scanning (Image Analyzer, Fullerton, CA).
Assays of DNA synthesis and migration
The DNA synthetic activity of HUVECs was measured by a [ 3 H] thymidine incorporation assay described previously (25) . In brief, HUVECs were plated onto gelatinized 24-well plates at a density of 2×10 4 The migration assay with HUVECs was performed using a modified Boyden chamber as described previously (26) . Growth factors in M199 containing 1% bovine serum albumin (BSA) were placed in the bottom wells of the chamber. Polycarbonate filters with 8-µm pores (Poretics, Livermore, CA) were coated with 0.2% gelatin and placed between the test substances and the upper chambers. Cells were trypsinized, washed twice in M199, and resuspended in M199 containing 1% BSA. We placed 2×10 5 cells into each well in the upper chamber and then incubated them for 12 h at 37°C in a humidified chamber with 5% CO 2 . After incubation, the nonmigrated cells were removed from the upper side of the filters with a cotton ball. The filters were fixed with methanol, mounted onto microscope slides, and stained with Diff-Quik solution. The migrated cells were counted at 100× magnification, using a microscope. VEGF (10 ng/ml) was used as a positive control.
Sprouting assays
The sprouting assay with PPAECs was performed as described previously (24) . In brief, PPAECs were grown to confluence on a culture dish. The placement of microcarrier beads (175 µm diameter) onto a confluent monolayer of PPAECs for 2-3 days produces beads covered by a confluent monolayer of cells. Beads were placed in a 6 mg/ml fibrinogen gel containing 2.0% heat-inactivated FBS. Fibrin gels were incubated in Dulbecco's modified Eagle's medium (DMEM) with a daily addition of control buffer, AM (10 −7 mol/l), VEGF (10 ng/ml), or AM plus wortmannin (30 nmol/l) and PD98059 (2 µmol/l). After 2 days, two independent, blinded investigators counted the number of endothelial sprouts. To quantify the degree of endothelial sprouting, two methods were used. Using an inverted microscope (Zeiss, Gottingen, Germany), we counted the number of endothelial sprouts with length exceeding the diameter of the microcarrier bead (long endothelial sprouts). We also assessed the total number of endothelial sprouts visible (total endothelial sprouts).
In vitro and in vivo angiogenesis assays
In vitro tube formation was performed in three-dimensional cultures of HUVECs on gel matrices with rat tail collagen (type I; Roche Molecular Biochemicals, Indianapolis, IN) at a final concentration of 1.75 mg/ml. The collagen solution was prepared in M199 culture medium with fibronectin (90 mg/ml), 150 mM HEPES, and sodium bicarbonate, neutralizing the pH by the addition of 1 M NaOH. HUVECs were added immediately to a final concentration of 2×10 6 cells/ml. The cell-collagen mixture (0.5 ml each) was added to 24-well dishes and placed in a humidified CO 2 incubator at 37°C for 30 min, allowing the gel to solidify. The medium without FBS was supplemented with or without AM and the indicated kinase inhibitors. AM and kinase inhibitor were replenished every 24 h. Tube formation in each well was monitored, and photos were taken at 48 h using an inverted microscope (Zeiss).
A Matrigel plug assay was performed as described previously (27) . In brief, C57/BL6 mice were injected s.c. with 0.5 ml of Matrigel with heparin (50 U/ml) that contained control buffer, AM, or AM plus wortmannin (30 nmol/l) and PD98059 (2 µmol/l). All three gels were injected into the same animal at different locations on the flanks in order to avoid individual variation. Each portion of injected Matrigel rapidly formed a single solid gel plug. After 2 wk, mice were killed, and the Matrigel plugs were recovered, fixed with 4% paraformaldehyde in PBS, embedded in paraffin, sectioned, and stained with Mason-Trichrome solution for microscopic observation. To quantify the formation of functional neovessels in Matrigel, the amount of hemoglobin in each plug was assayed according to the manufacturer's protocol (Drabkin reagent kit 525, SigmaAldrich).
Data analyses
Data are expressed as mean ±SD. Statistical significance was tested using one-way ANOVA followed by the Student-Newman-Keuls test. Statistical significance was set at P<0.05.
RESULTS
AM induces Akt, ERK1/2, and p125
FAK phosphorylation
Activation of Akt, ERK, and p125 FAK in endothelial cells plays an important role in angiogenesis (24, 28, 29) . To determine Akt activity, we measured the phosphorylation of Akt. AM (10 −7 mol/l) increased Akt phosphorylation as early as 10 min and produced a maximal effect at 30 min (Fig. 1A) . The maximum mean increase in Akt phosphorylation was 6.2-fold. AM (10 −11 -10 −7 mol/l) increased Akt phosphorylation in a dose-dependent manner (Fig. 1D ). To determine MAPK activity, we measured the phosphorylation of two MAPKs, ERK1 (p44 MAPK ) and ERK2 (p42 MAPK ). AM (10 −7 mol/l) increased ERK1/2 phosphorylation as early as 5 min and produced a maximal effect at 10 min (Fig. 1B) . These effects declined and returned to control levels at 30 min. The maximum mean increase in ERK2 phosphorylation was 7.1-fold. AM (10 −11 -10
mol/l) also increased ERK1/2 phosphorylation in a dose-dependent manner (Fig. 1E) . To examine p125 FAK activity, we measured the tyrosine phosphorylation of p125 FAK . AM (10
mol/l) induced p125 FAK phosphorylation as early as 5 min and produced a maximal effect at 10 min (Fig. 1C) . These effects declined but continued to be higher than control levels at up to 15 min. The maximum mean increase in p125 FAK was 3.7-fold. Thus, the AM-induced phosphorylation of p125 FAK and ERK1/2 peaked at the same time. AM (10 −11 -10 −7 mol/l) also induced p125 FAK phosphorylation in a dose-dependent manner (Fig. 1F ).
AM mediates phosphorylation of Akt and ERK, using distinct signaling pathways, and the phosphorylation effect of AM is partially inhibited by AM 22-52
The Western blot analysis in Figure 1 demonstrated AM-dependent activation of Akt and ERK1/2 in HUVECs. To rule out any crosstalk between the two pathways activated by AM (10
mol/l), we investigated the effect of the PI3′-kinase inhibitor, wortmannin on ERK1 and ERK2 phosphorylation and MEK1/2 inhibitor, PD98059 on Akt phosphorylation. Although 30 nmol/l of wortmannin was sufficient to inhibit AM-induced phosphorylation of Akt ( Fig. 2A) , this dosage had no effect on ERK1 and ERK2 phosphorylation (Fig. 2B) . On the other hand, the MEK1/2 inhibitor, PD98059 significantly inhibited AM-induced phosphorylation of ERK1 and ERK2 ( Fig. 2B ) but had no effect on the phosphorylation of Akt ( Fig. 2A) . We conclude, therefore, that AM mediates phosphorylation of Akt and MAPK, using distinct signaling pathways. In addition, we tested the effect of these inhibitors on AM-induced p125 FAK phosphorylation. Pretreatment of PI 3′-kinase-specific inhibitor, wortmannin (30 nmol/l), almost totally abolished the AM-induced p125 FAK phosphorylation (Fig. 2C) . However, pretreatment of PD98059 (50 nmol/l) only partially reduced p125 FAK phosphorylation (Fig. 2C ). This finding suggests that AM-induced p125 FAK phosphorylation is mainly regulated by a PI 3′-kinase dependent pathway.
AM is a putative inhibitor of the AM receptor. We tested the effect of AM 22- (Fig. 2D, 2E , and 2F). These results support the idea that phosphorylation of Akt, ERK1/2, and p125 FAK by AM is partially mediated through AM 22-52 -sensitive receptors.
AM increases DNA synthesis and migration in endothelial cells
MAPK and Akt participate in protein kinase cascades that play critical roles in the regulation of cell growth and migration (28) (29) (30) (31) . Because ERK1/2 and Akt activation might be involved in the proliferation and migration in endothelial cells, we examined the effect of AM on endothelial cell DNA synthesis and migration. (Fig. 3A) . These data demonstrated that AM increased DNA synthesis in a dose-dependent manner.
To examine whether AM affects endothelial cell migration, we pretreated HUVECs with these compounds and placed them into a Boyden chamber in the absence or presence of AM (10 −11 -10 −7 mol/l). Aftr a 12-h treatment, AM (10 −7 mol/l) increased the migration of HUVECs approximately fourfold, while VEGF (10 ng/ml) increased migration approximately sixfold (Fig.  3B) . These results indicated that AM stimulated endothelial migration in a dose-dependent manner.
AM induces tube formation by endothelial cells in collagen gel
Endothelial cells form as a precursor to blood vessel formation (31) . Well-known endothelial growth factors, including VEGF and angiopoietin-1, increase tube formation of endothelial cells through enhanced migration (24, 32, 33) . Because our data indicated that AM is a relatively strong enhancer of migration, we examined the effect of AM on tube formation of HUVECs in type I collagen gel. After a 48-h treatment, AM (10 −7 mol/l) and VEGF (10 ng/ml) increased tube formation ~3.1-fold and 4.0-fold, respectively (Fig. 4A, 4B ). MEK1/2 inhibitor, PD98059, and PI 3′-kinase inhibitor, wortmannin, significantly suppressed AM-induced tube formation (Fig.  4A, 4B ). The inhibitors alone mildly suppressed basal tube formation at 48 h, but not at a statistically significant level (Fig. 4B ). These data suggest that AM-induced tube formation in endothelial cells is mediated through PI 3′-kinase and the MEK1/2 pathway.
AM induces sprouting in PPAECs
Sprouting, an essential step in initial phase of angiogenesis, requires cell migration, cell proliferation, and tube formation (31, 34) . Because AM induced cell migration, cell proliferation, and tube formation, we evaluated the effect of AM on sprouting in PPAECs. We used two assays in PPAECs to quantify the degree of sprouting caused by AM. After 48 h, AM (10 −7 mol/l) increased the total number of total endothelial spouts and long endothelial sprouts ~2.9-fold and 2.5-fold, respectively (Fig. 5A , 5B). As a positive control, VEGF (10 ng/ml) increased the total number of endothelial spouts and long endothelial sprouts ~4.0-fold and 3.5-fold, respectively (Fig. 5A , 5B). Thus, the relative potency of VEGF in endothelial sprouting formation was higher than that produced by AM. MEK1/2 inhibitor, PD98059, or PI 3′-kinase inhibitor, wortmannin, partially suppressed AM-induced sprouting (Fig. 5A , 5B). The inhibitors alone mildly suppressed basal sprouting at 48 h, but not at a statistically significant level (data not shown). The relative inhibitory potency, judged by the total number of endothelial sprouts, was higher for wortmannin than for PD98059 (Fig. 5B) . However, the relative inhibitory potency evaluated by the number of long endothelial sprouts was similar for the two inhibitors (Fig. 5B) . The combination of PD98059 and wortmannin completely inhibited AM-induced endothelial sprouting formation in PPAECs. Although AM-induced sprout formation is mediated through PI 3′-kinase and the MEK1/2 pathway, the major signaling is through a PI 3′-kinase-dependent pathway.
AM promotes angiogenesis in vivo
To determine whether AM is capable of promoting angiogenesis in vivo, we performed an established in vivo angiogenesis assay, the mouse Matrigel plug assay. Histochemical staining indicated that Matrigel containing AM (2×10 −7 mol/l) produced more neovessels within gels than Matrigel containing control buffer (Fig. 6A) . Matrigel containing AM (2×10 −7 mol/l) had more hemoglobin content than Matrigel containing control buffer (Fig. 6B) . Addition of PD98059 plus wortmannin suppressed these AM-induced angiogenic activities (Fig. 6A, 6B ). When quantified by measurement of hemoglobin in the Matrigels, the angiogenic activity of AM was comparable to that of 20 ng/ml of VEGF (data not shown). Thus, AM has an angiogenic activity in vivo through activation of ERK and Akt.
DISCUSSION
In this report, we demonstrate that AM induces angiogenesis through intracellular Akt, MAPK, and p125 FAK activation in endothelial cells. Accordingly, AM promoted endothelial DNA synthesis, migration, and tube formation, which are the essential steps for angiogenesis. Indeed, AM promoted sprouting in vitro and neovessel formation in vivo in gel plugs. Thus, we demonstrate here the signaling pathways of AM in angiogenesis (Fig. 1, 2) .
Activation of MAPK and Akt in endothelial cells is a crucial intracellular signaling step for angiogenesis (29, 30) . Growth factors such as VEGF or angiopoietin-1 bind to their receptor tyrosine kinases in endothelial cells and induce angiogenesis through activation of these kinases (24, (28) (29) (30) . Our Western blot analyses indicated that AM induced phosphorylation of Akt and ERK in HUVECs, and AM fragment, AM partially suppressed AM-induced phosphorylation of Akt and ERK. Therefore, AM-induced activation of Akt and ERK could occur, at least in part, through an AM 22-52 -sensitive receptor. Our Western blot data also suggest that there is no crosstalk between AM-induced Akt and ERK pathways. Thus, AM mediates phosphorylation of Akt and ERK, using distinct signaling pathways. Using thin-layer chromatography, we also found that AM (10 −8 mol/l) caused maximal activation of PI 3′-kinase activity within 3-5 min in
HUVECs (data not shown). Thus, AM-induced Atk activation can be mediated through activation of PI 3′-kinase.
A functional AM receptor consists of two proteins, CRLR and the RAMPs, that couple the receptor to the cellular signal transduction pathway. Because CRLR is a G protein-coupled receptor, we wanted to know whether the Gαi-protein is involved in the PI 3′-kinase pathway. HUVECs were pretreated with a Gαi/o protein inhibitor, pertussis toxin (200, 400, and 800 ng/ml), or control buffer for 2 h. Then the cells were incubated in medium containing 1% serum and AM (10 −7 mol/l) for 3 min. The PI 3′-kinase assay was performed. Pertussis toxin reduced AM-induced phosphorylation of PI 3′-kinase activity (AM alone, 5.7±1.4; AM + 200 ng/ml pertussis toxin, 3.5±0.7; AM + 400 ng/ml pertussis toxin, 1.9±0.5; AM + 800 ng/ml pertussis toxin, 1.6±0.5; control, 1.0±0.0). These results suggested that AM-induced phosphorylation of PI 3′-kinase occurs through a G protein-coupled receptor, probably CRLR.
In the initial phase of angiogenesis and neovascularization, the sprouting of endothelial cells is an essential step (31) . This process requires cell migration, cell proliferation, and tube formation (31). Our results showed that AM induced proliferation, migration, and tube formation in endothelial cells in vitro (Fig. 4, 5) . We also confirmed that AM induced sprouting from endothelial cells. Furthermore, we demonstrated that AM-induced sprout formation was mediated through PI 3′-kinase and MEK1/2 pathway.
A member of the nonreceptor protein tyrosine kinases, p125 FAK , has been implicated in the regulation of the actin cytoskeleton during migration (35) . p125
FAK is activated by tyrosine phosphorylation, which is induced by growth factors (24, 36, 37) . Because AM has a migratory effect in endothelial cells, we examined whether AM could stimulate p125 FAK . In this study, we found that AM induces tyrosine phosphorylation of p125 FAK in a time-and concentrationdependent manner in endothelial cells (Fig. 1) . Next, we found that the PI 3′-kinase inhibitors completely inhibit AM-stimulated tyrosine phosphorylation of p125 FAK in HUVECs. These results suggest that PI 3′-kinase is part of the signal transduction pathway inducing the tyrosine phosphorylation of p125 FAK . Because p125 FAK has been implicated in migration, all of these results suggest that the migratory effect of AM in endothelial cells may be mediated through AM-induced tyrosine-phosphorylated p125
FAK by a PI 3′-kinase-dependent pathway.
It is well known that endothelial cell survival is an essential prerequisite for DNA synthesis and migration. Previously, Kato et al. (9) reported that AM is an endothelial cell survival factor. We also demonstrated that the antiapoptotic effect of AM is associated with Akt pathway activation (23) . Because AM is a survival factor for endothelial cells, AM could have an angiogenic role in vascular endothelial cells. To produce sprouting in response to AM stimulation in an in vitro fibrin gel, endothelial cells must release proteinases to degrade extracellular matrix for their migration (38, 39) . One family of such enzymes is the matrix metalloproteinases (MMPs) (40) . We found that AM stimulated the hydrolytic activities of plasmin, MMP-2, and MMP-9 in HUVECs measured by gelatin zymography, and furthermore that these induced activities were inhibited by PI 3′-kinase inhibitors (data not shown). Thus, these two findings give additional evidence that AM is an angiogenic factor in vitro.
We wondered whether the effect of AM might rely on an indirect effect through some other angiogenic factor. Thus, we examined the changes in VEGF-A and angiopoietin-2 mRNAs after treatment with AM (10 −7 mol/l). An RNase protection assay in HUVECs showed that AM did not significantly change the mRNA expression of VEGF-A or angiopoietin-2 for 0, 2, 4, and 6 h (data not shown). Thus, these data suggested that AM did not change VEGF-A and angiopoietin-2.
We confirmed the angiogenic activity of AM by performing an in vivo mouse Matrigel plug assay. AM promoted neovessel formation in the Matrigel plug, and we noted that these newly synthesized vessels participated actively in the circulation of blood cells. Moreover, our pharmacological inhibition study indicated that the activation of MAPK and Akt by AM is crucial in endothelial tube formation and neovessel formation in the Matrigel plug. These results suggest that the activities and pathways of AM found in our in vitro experiments are likely to be valid in vivo as well. Taken together, these data show that the AM-induced angiogenic process may be accomplished by and mainly mediated through intracellular PI 3′-kinase/Akt -p125 FAK and Ras/Raf/MEK/ERK1/2 activation (Fig. 7) .
In tumor cells, AM may have a significant role in angiogenesis. Because angiogenesis is an essential process in tumor-host interactions for tumor growth, maintenance, and metastasis, finding ways to regulate the action of AM may provide a new avenue for finding anticancer therapeutics.
Until recently, fibroblast growth factor, platelet-derived growth factor, VEGF, and angiopoietin-1 were known to have profound angiogenic effects in endothelial cells. In this study, we demonstrated that AM is a new angiogenic factor and its signaling is mediated through activation of Akt, MAPK, and focal adhesion kinase in endothelial cells. These results suggest that AM is a candidate for therapeutic angiogenesis or vasculogenesis in ischemic disease. Further studies are needed to assess the pathogenic role of AM in vascular diseases, therapeutic endothelial survival, and the counteractive or additive effect of AM with other angiogenic factors. supplemented with 20% serum. After 18 h in culture medium with 1% FBS, control buffer (CB), AM (10 -7 mol/l), or VEGF (10 ng/ml) was added in M199 medium supplemented with 2% serum. At 48 h, the DNA amount was measured by [ 3 H] thymidine incorporation assay. Thymidine incorporation in CB was arbitrarily set at 100. B) The bottom wells of the chamber were filled with M199 containing 1% bovine serum albumin and CB, AM (10 -7 mol/l), or VEGF (10 ng/ml). HUVECs (2. 
. The downstream pathways are associated with endothelial proliferation, migration, and tube formation. In addition, AM induces sprouting in vitro. Taken together, these cellular processes promote angiogenesis in vivo.
